Clinical trials: Craniosynostosis
Craniosynostoses
Investigation of Anthropometric Properties of Babies With Craniosynostosis
Craniosynostosis is a malformation affecting the head and face, in which one or more sutures in the skull are fused prematurely.
- Trial name
- NCT04827524
- Testing
- Anthropometric measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Yuksek Ihtisas University
Craniosynostoses, Crouzon Syndrome
ASO Treatment for Syndromic Craniosynostoses
Syndromic craniosynostoses (SCS) are rare genetic disorders defined by premature cranial suture fusion, resulting in abnormal craniofacial development and constrained brain growth.
- Conditions
- Craniosynostoses, Crouzon Syndrome, Saethre Chotzen Syndrome, Muenke Syndrome
- Trial name
- NAUTILUS (NCT07535372)
- Testing
- Design of patient specific ASO
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Craniosynostosis
Child and Infant Learning Project
To learn more about the cognitive and motor development of infants and young children born with a craniofacial defect called craniosynostosis.
- Trial name
- CILP (NCT00077831)
- Testing
- neurobehavioral development
- Where
- 4 sites in United States
- Volunteers
- 535 people
- Sponsor
- Seattle Children's Hospital
Head-and-Neck Squamous Cell Carcinoma
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.
Investigation of the molecular mechanism and clinical significance of the interplay between Twist1 and other EMT regulators through microRNA-29 family.
- Trial name
- NCT01927354
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Craniosynostoses
EPBONF : Evaluation of the Safety and Effectiveness of a Medical Device Aimed at Guiding Orbito-naso-frontal Band Surgery, for the Treatment of Craniostenoses
Craniostenosis is a congenital disorder caused by early fusion of the cranial sutures between the skull bones, resulting in orbito-naso-frontal deformities.
- Trial name
- EPBONF (NCT06366178)
- Testing
- BONFIX system
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Solid Tumors
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.
- Trial name
- NCT03235570
- Testing
- Pemigatinib
- Where
- 12 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Incyte Corporation
Plagiocephaly, Scaphocephaly
Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU
Many hospitalized infants can develop a flattening of the back or sides of their head. This condition develops gradually when an infant's head rests on a firm or semi-firm surface for a prolonged period of time.
- Conditions
- Plagiocephaly, Scaphocephaly, Brachycephaly
- Trial name
- NCT01218087
- Testing
- Cranial cup device and Moldable positioner, Moldable positioner device
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Boston Children's Hospital
Craniosynostosis
Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their Care
The purposes of this study are: to better understand the experience of the announcement for the diagnostic of craniosynostosis to patients and their families to improve the understanding of it and it modes of appropriation to…
- Trial name
- AmAc (NCT02287805)
- Testing
- qualitative survey, quantitative survey
- Where
- France
- Volunteers
- 574 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with…
- Trial name
- FOENIX-BTC (NCT07710885)
- Testing
- Futibatinib, Zimberelimab, Durvalumab
- Where
- 21 sites in Australia, Japan and 2 more
- Volunteers
- 784 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Chronic Subdural Hematoma, Recurrence
High Concentration Oxygen for Pneumocephalus After Evacuation of Chronic Subdural Haematoma
Normobaric oxygen therapy was shown to be effective in reducing post craniotomy pneumocephalus. Theoretical assessment of normobaric oxygen therapy in treating pneumocephalus has shown that a higher level of oxygen concentration…
- Conditions
- Chronic Subdural Hematoma, Recurrence, Oxycephaly
- Trial name
- HOPE (NCT04725851)
- Testing
- High concentration Oxygen therapy, Control: Room Air or Low concentration Oxygen
- Where
- Hong Kong
- Volunteers
- 36 people
- Sponsor
- Chinese University of Hong Kong
Squamous-cell Non-small Cell Lung Cancer
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
A recent investigation showed that a substantial proportion of patients with SQCLC (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA) and are potentially sensitive to…
- Trial name
- NCT03762122
- Testing
- Rogaratinib
- Where
- 11 sites in Switzerland
- Volunteers
- 15 people
- Sponsor
- Swiss Cancer Institute
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
- Trial name
- NCT01928459
- Testing
- BGJ398, BYL719
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Craniosynostosis, Strabismus
Ocular Characteristics in Patients With Craniosynostosis
Craniosynostosis are cranial deformations due to the premature closure of one or more cranial sutures. These deformations affect approximately one in 2.500 births.
- Conditions
- Craniosynostosis, Strabismus, Intracranial Hypertension, Amblyopia
- Trial name
- COPACA (NCT06928727)
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Advanced Cancer
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules called "angiogenic factors" that may cause tumors to grow.
- Trial name
- NCT02747797
- Testing
- Lucitanib
- Where
- United States
- Sponsor
- Teresa Helsten, MD
Craniosynostosis Repair, Untethering of Cord
The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITU
Postoperative pain is a major concern in routine management of children admitted to pediatric intensive care treatment. There are significant negative physiological and psychological ramifications of postoperative pain such as…
- Trial name
- NCT01996163
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family.
- Conditions
- Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- TAGNOT (NCT07292168)
- Testing
- humanized monoclonal anti-FGFR1 antibody OM-RCA-01
- Where
- 5 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Kidney Cancer Research Bureau
Craniosynostosis, Sagittal, Scaphocephaly
Examination of Neuromotor Development of Cases Diagnosed with Scaphocephaly
It's an observational study. Purpose of the study: To evaluate the neuromotor development of scaphocephaly cases. 21 infants diagnosed with scaphocephaly aged 2-17 months were included.
- Conditions
- Craniosynostosis, Sagittal, Scaphocephaly, Developmental Delay
- Trial name
- NCT06294626
- Testing
- Group 1
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Acıbadem Atunizade Hospital
Solid Tumor Malignancy
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR…
- Trial name
- NCT03822117
- Testing
- Pemigatinib
- Where
- 90 sites in United States, Denmark and 9 more
- Volunteers
- 111 people
- Sponsor
- Incyte Corporation
Cholangiocarcinoma
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
- Trial name
- NCT02924376
- Testing
- Pemigatinib
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 147 people
- Sponsor
- Incyte Corporation